Evaluation of the effects of celecoxib on mouse lymphoma cells (EL4)
Subject Areas : Journal of Comparative Pathobiology
Leyla Emami
1
(
Doctor of Veterinary Medicine, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
)
Sh Safi
2
(
.Department of Pathology and Clinical Pathology, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran.
)
Farhad Zaker
3
(
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
)
Keywords: Celecoxib, Apoptosis, EL4 cell line, Mouse, Lymphoma,
Abstract :
Lymphoma is one of the most common tumors in most species of the mouse. On the other hand, biologic, histopathologic and epidemiological characteristics of mouse lymphoma are similar to lymphoma in humans. Hence, tumor lymphoma in mice can be a suitable model for the biological study of human cancers. The objective of the present study was to evaluate the apoptotic and cytotoxic effects of celecoxib on mouse lymphoma tumor cells (EL4) using Annexin/PI and MTT assays. The results of MTT showed a dose and time-dependent inhibition of EL4 cells by celecoxib and 50% inhibition of cell survival at 20 μm of celecoxib. In addition, the percentage of cells with apoptosis increased after 48 hours exposure to IC50 concentration (50% survival of the exposed cells) of celecoxib. Based on the obtained results, it seems that celecoxib can be used as an adjunct therapy along with other compounds used to treat lymphoma in mice and probably in human medicine.
_||_
Awara WM, El-Sisi AE, El-Sayad ME, Goda AE. (2004): The potential role of cyclooxygenase-2 inhibitors in the treartment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacol. Res. 50(5):487-498.
10.Galloet AS, Travert M, Bepoldin LB, Trate K, Lamy T, Guilloton F, Pangault C, Laugendre SC, guillaudeux T.( 2014): COX-2 independent effects of celecoxib sensitize Lymphoma B cells to TRAIL-mediated apoptosis. Clin. Cancer Res. 20 (10): 2663-2673.